Pooled data from Phase II studies (AIRLEAF®, CLAIRLEAF®) of the cathepsin C (CatC, or DPP1) inhibitor BI 1291583 in bronchiectasis - Amsterdam 2025

Bronchiectasis: immunology, biomarkers, molecular profiles and targeted therapy

Chair(s): Eva Polverino, Merete Bridget Long

Session type: Poster session

Pooled data from Phase II studies (AIRLEAF®, CLAIRLEAF®) of the cathepsin C (CatC, or DPP1) inhibitor BI 1291583 in bronchiectasis

Michal Shteinberg

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Azurocidin-1 induces epithelial dysregulation in airway epithelial cells: implications for bronchiectasis treatment

Max Schwiening

Poster

Abstract

The airway interferon landscape is altered in bronchiectasis and differs according to anatomical site

Joanne Mckenzie

Poster

Abstract

Adaptive immunity impairment in bronchiectasis: crosstalk of immunomodulatory cells and lymphocytes

Nikoleta Bizymi

Poster

Abstract

EMBARC-BRIDGE: a representative biorepository to support translational research in bronchiectasis

Morven Shuttleworth

Poster

Abstract

Profiling peripheral blood neutrophils in patients with bronchiectasis: an EMBARC study

Chloe Hughes

Poster

Abstract

Inflammatory markers in high bacterial load infections in bronchiectasis

Rebecca C Hull

Poster

Abstract

Distinct IL-1? and TNF driven inflammatory responses in Non-typable Haemophilus influenzae infection in bronchiectasis

Rachel Galloway

Poster

Abstract

Neutrophil extracellular traps, disease severity and airway infection in bronchiectasis: preliminary results from the BRILLIANT study

Merete Bridget Long

Abstract

Stiff circulating neutrophils and enhanced thrombogenic potential in bronchiectasis increases cardiovascular risk

Rebecca Evans

Poster

Abstract

Factors related to the epigenetic profile in bronchiectasis

Lídia Perea

Poster

Abstract

CC16: a biomarker of disease severity and Pseudomonas infection in Bronchiectasis

Pau Marrades Segura

Poster

Abstract

Neutrophil elastase activity following cathepsin C (CatC, or DPP1) inhibition with BI 1291583 in people with bronchiectasis

James D. Chalmers

Poster

Abstract

Association between neutrophil elastase activity in bronchial lavage fluid and the one-year follow-up exacerbation in bronchiectasis patients

Ho Lam Nguyen

Poster

Abstract

Subgroup analysis: AIRLEAF® Phase II study of a cathepsin C (CatC, or DPP1) inhibitor, BI 1291583, in adults with noncystic fibrosis bronchiectasis

James D. Chalmers

Poster

Abstract

Pooled data from Phase II studies (AIRLEAF®, CLAIRLEAF®) of the cathepsin C (CatC, or DPP1) inhibitor BI 1291583 in bronchiectasis

Michal Shteinberg

Poster

Abstract

Efficacy and safety of brensocatib in patients with non-cystic fibrosis bronchiectasis and Pseudomonas aeruginosa infection: Analysis of the ASPEN trial

Stefano Aliberti

Poster

Abstract

Effectiveness of mucoactives compared to standard care in adult bronchiectasis: A systematic review

Benjamin Mccullough

Poster

Abstract

Efficacy and safety of brensocatib in Japanese patients with non-cystic fibrosis bronchiectasis: Analysis of the ASPEN trial

Kozo Morimoto

Poster

Abstract

Expression of activation markers of circulating neutrophils and eosinophils in stable bronchiectasis

Andreas M. Matthaiou

Poster

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}